Key facts
- This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Feb 2022, 18:06.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
Additional SEC filing notes
Footnote F1
Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Footnote F2
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.76 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F3
Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Footnote F4
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.99 to $81.36 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F5
Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Footnote F6
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.96 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.